Perospirone in the treatment of schizophrenia: Effect on verbal memory organization

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 30, Issue 2, 2006, Pages 204-208

  Araki, Tsuyoshi ^a   Yamasue, Hidenori ^a   Sumiyoshi, Tomiki ^b   Kuwabara, Hitoshi ^a,c,d   Suga, Motomu ^c,e   Iwanami, Akira ^f   Kato, Nobumasa ^a   Kasai, Kiyoto ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

^c Kaijoryo Hospital   (Japan)

^d TOKYO METROPOLITAN MATSUZAWA HOSPITAL   (Japan)

^e TOKYO METROPOLITAN BOKUTOH HOSPITAL   (Japan)

^f AINO UNIVERSITY   (Japan)

Author keywords

5 HT1A receptors; Atypical antipsychotics; Cognitive function; Memory organization; Perospirone; Schizophrenia

Indexed keywords

BIPERIDEN; BROMPERIDOL; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; PERICIAZINE; PEROSPIRONE; QUETIAPINE; SEROTONIN 1A AGONIST; SEROTONIN 2A ANTAGONIST;

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITION; DRUG MECHANISM; DRUG SUBSTITUTION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; LEARNING TEST; MALE; MENTAL PATIENT; SCHIZOPHRENIA; SYMPTOM; VERBAL MEMORY;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; INDOLES; MALE; MEMORY; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; STATISTICS, NONPARAMETRIC; THIAZOLES; VERBAL LEARNING;

EID: 33344461704     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2005.10.015     Document Type: Article

References (50)

1. N.C. Andreasen, P. Nopoulos, D.S. O'Leary, D.D. Miller, T. Wassink, and M. Flaum Defining the phenotype of schizophrenia: cognitive dysmetria and its neural mechanism Biol Psychiatry 46 1999 908 920
2. T.R. Barnes A rating scale for drug-induced akathisia Br J Psychiatry 154 1989 672 676
3. A.K. Bousfield, and W.A. Bousfield Measurement of clustering and of sequential constancies in repeated free recall Psychol Rep 19 1966 935 942
4. R.W. Buchanan, C. Holstein, and A. Breier The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance Biol Psychiatry 36 1994 717 725
5. D.E. Casey Tardive dyskinesia and atypical antipsychotic drugs Schizophr Res 35 Suppl. 1999 S61 S66 [Review]
6. M.B. First, R.L. Spitzer, M. Gibbon, and J.B.W. Williams Structured clinical interview for DSM-IV Axis I disorders 1997 Biometrics Research Department, New York State Psychiatric Institute New York [Japanese translation: Kitamura, T., Okano, T., 2003. Tokyo: Nihon Hyoron-sha publishers]
7. J.M. Gold, C. Randolph, C.J. Carpenter, T.E. Goldberg, and D.R. Weinberger Forms of memory failure in schizophrenia J Abnorm Psychology 101 1992 487 494
8. M.F. Green What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153 1996 321 330
9. M.F. Green, B.D. Marshall Jr., W.C. Wirshing, D. Ames, S.R. Marder, and S. McGurk Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 154 1997 799 804
10. C. Hagger, P. Buckley, J.T. Kenny, L. Friedman, D. Ubogy, and H.Y. Meltzer Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine Biol Psychiatry 34 1993 702 712
11. P.D. Harvey, and R.S.E. Keefe Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment Am J Psychiatry 158 2001 176 184
12. P.D. Harvey, H. Meltzer, G.M. Simpson, S.G. Potkin, A. Loebel, and C. Siu Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia Schizophr Res 66 2004 101 113
13. T. Hashimoto, N. Nishino, H. Nakai, and C. Tanaka Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia Life Sci 48 1991 355 363
14. A.L. Hoff, W.O. Faustman, M. Wieneke, S. Espinoza, M. Costa, and O. Wolkowitz The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients Neuropsychopharmacology 15 1996 361 369
15. J. Ichikawa, H. Ishii, S. Bonaccorso, W.L. Fowler, I.A. O'Laughlin, and H.Y. Meltzer 5-HT2A and D2 receptor blockage increases cortical DA release via 5-HT1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release J Neurochem 76 2001 1521 1531
16. A. Inagaki, T. Inada, Y. Fujii, and G. Yagi Dose equivalence of neuroleptics A. Inagaki T. Inada Y. Fujii G. Yagi T. Yoshio H. Nakamura T. Yamauchi Dose equivalence of psychotropic drugs 1999 Seiwa Publishers Tokyo 11 60 [in Japanese]
17. A. Inagaki, T. Inada, Y. Fujii, and G. Yagi Dose equivalence of anti-cholinergic drugs A. Inagaki T. Inada Y. Fujii G. Yagi T. Yoshio H. Nakamura T. Yamauchi Dose equivalence of psychotropic drugs 1999 Seiwa Publishers Tokyo 61 76 [in Japanese]
18. A. Inagaki, T. Inada, Y. Fujii, and G. Yagi Dose of equivalence of psychotropic drugs. Part XV-dose of novel neuroleptics Perospirone, Jpn J Clin Psychopharmacol 4 2001 869 870 [in Japanese]
19. M. Iwakawa, T. Terao, A. Soya, H. Kojima, Y. Inoue, and N. Ueda A novel antipsychotic, perospirone, has antiserotonergic and antidopaminergic effects in human brain: findings from neuroendocrine challenge tests Psychopharmacology 176 2004 407 411 [May 25, Electronic publication ahead of print]
20. T. Kato, A. Hirose, Y. Ohno, H. Shimizu, H. Tanaka, and M. Nakamura Binding profile of SM-9018, a novel antipsychotic candidate Jpn J Pharmacol 54 1990 478 481
21. S.R. Kay, A. Fiszbein, and L.A. Opler The positive and negative syndrome scale (PANSS) for schizophrenia Schizophr Bull 13 1987 261 276
22. R.S. Kern, M.F. Green, B.D. Marshall Jr., W.C. Wirshing, D. Wirshing, and S.R. McGurk Risperidone versus haloperidol on secondary memory: can newer medications aid learning? Schizophr Bull 25 1999 223 232
23. T. Koyama, Y. Nakajima, T. Fujii, and K. Kawashima Enhancement of cortical and hippocampal cholinergic neurotransmission through 5-HT1A receptor-mediated pathways by BAY x 3702 in freely moving rats Neurosci Lett 265 1999 33 36
24. M.A. Lee, P.A. Thompson, and H.Y. Meltzer Effects of clozapine on cognitive function in schizophrenia J Clin Psychiatry 55 Suppl B 1994 82 87
25. M.A. Lee, K. Jayathilake, and H.Y. Meltzer A comparison of the effects of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia Schizophr Res 37 1999 1 11
26. M.D. Lezak Verbal fluency M.D. Lezak Neuropsychological assessment third ed. 1995 Oxford University Press New York 544 546
27. J. Mauskopf, M. Muroff, P.J. Gibson, and D.L. Grainger Estimating the costs and benefits of new drug therapies: atypical antipsychotic drugs for schizophrenia Schizophr Bull 28 2002 619 635 [Review]
28. H.Y. Meltzer, and S.R. McGurk The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia Schizophr Bull 25 1999 233 255
29. H.Y. Meltzer, and T. Sumiyoshi Atypical antipsychotic drugs improve cognition in schizophrenia Biol Psychiatry 53 2003 265 267
30. H.Y. Meltzer, Z. Li, Y. Kaneda, and J. Ichikawa Serotonin receptors: their key role in drugs to treat schizophrenia Prog Neuropsychopharmacol Biol Psychiatry 27 2003 1159 1172
31. H.J. Moller Atypical neuroleptics: a new approach in the treatment of negative symptoms Eur Arch Psychiatry Clin Neurosci 249 Suppl 4 1999 99 107
32. M. Murasaki, I. Yamashita, Y. Machiyama, G. Yagi, K. Kamijima, and Y. Kudo Early phase II study of a new antipsychotic, perospirone HCl (SM-9018), on schizophrenia Kiso to Rinsho (Clinical Report) 31 1997 2159 2179 [in Japanese]
33. M. Murasaki, T. Koyama, Y. Machiyama, G. Yagi, K. Kamijima, and M. Toru Clinical evaluation of a new antipsychotic, perospirone HCl, on schizophrenia: a comparative double-blind study with haloperidol Clin Eval 24 1997 159 205 [in Japanese]
34. S. Nohara, M. Suzuki, M. Kurachi, I. Yamashita, M. Matsui, and H. Seto Neural correlates of memory organization deficits in schizophrenia: a single photon emission computed tomography study with 99m-Tc-ethyl-cysteinate dimmer during a verbal learning task Schizophr Res 42 2000 209 222
35. S.V. Onrust, and K. McClellan Perospirone CNS Drugs 15 2001 329 337 [discussion 338]
36. S.E. Purdon Cognitive improvement in schizophrenia with novel antipsychotic medications Schizophr Res 35 1999 S51 S60
37. S.E. Purdon, A. Labelle, and L. Boulay Neuropsychological change in schizophrenia after 6 weeks of clozapine Schizophr Res 48 2001 57 67
38. A.M. Rasmusson, L.E. Goldstein, A.Y. Deutch, B.S. Bunney, and R.H. Roth 5-HT1a agonist 8-OH-DPAT modulates basal and stress-induced changes in medial prefrontal cortical dopamine Synapse 18 1994 4218 4224
39. A. Rossi, F. Mancini, P. Stratta, P. Mattei, R. Gismondi, and F. Pozzi Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study Acta Psychiatr Scand 95 1997 40 43
40. A. Schotte, P. Bonaventure, P.F. Janssen, and J.E. Leysen In vitro receptor binding and in vivo receptor occupancy in rat and guinea pig brain: risperidone compared with antipsychotics hitherto used Jpn J Pharmacol 69 1995 399 412
41. G.M. Simpson, and J.W. Angus A rating scale for extrapyramidal side effects Acta Psychiatr Scand Suppl 212 1970 11 19
42. J.M. Smith, L.T. Kucharski, W.T. Oswald, and L.J. Waterman A systematic investigation of tardive dyskinesia in inpatients Am J Psychiatry 136 1979 918 922
43. J.S. Sprouse, L.S. Reynolds, J.P. Braselton, H. Rollema, and S.H. Zorn Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation Neuropsychopharmacology 21 1999 622 631
44. T. Sumiyoshi, and H.Y. Meltzer Serotonin 1A receptors in memory function Am J Psychiatry 161 2004 1505
45. T. Sumiyoshi, C.A. Stockmeier, J.C. Overholser, G.E. Dilley, and H.Y. Meltzer Serotonin 1A receptors are increased in postmortem prefrontal cortex in schizophrenia Brain Res 708 1996 209 214
46. T. Sumiyoshi, M. Matsui, I. Yamashita, S. Nohara, T. Uehara, and M. Kurachi Effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory function in schizophrenia J Clin Psychopharmacol 20 2000 386 388
47. T. Sumiyoshi, M. Matsui, S. Nohara, I. Yamashita, M. Kurachi, and C. Sumiyoshi Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment Am J Psychiatry 158 2001 1722 1725
48. T. Sumiyoshi, M. Matsui, I. Yamashita, S. Nohara, M. Kurachi, and T. Uehara The effect of tandospirone, a serotonin (1A) agonist, on memory function in schizophrenia Biol Psychiatry 49 2001 861 868
49. R. Tandon, and M.D. Jibson Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome Ann Clin Psychiatry 14 2002 123 129
50. L. Voruganti, L. Cortese, L. Owyeumi, V. Kotteda, Z. Cernovsky, and S. Zirul Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study Schizophr Res 57 2002 201 208